The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines

Ranibizumab biosimilar is being launched in major European markets. Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane Biopharma, marking Xbrane’s first commercial

The Roddenberry Foundation has announced the six awardees of its biennial 1.5 million USD Prize to support audacious early-stage science and technology ventures that contribute to the United Nations Development

Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2

The company has been awarded a grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge hospital and Karolinska Institute. The grant will fund

Modus Therapeutics secures access to bridge financing from longstanding investor Karolinska Development. Access to this funding ensures that momentum of clinical development of Modus’ lead asset, sevuparin, will be enhanced

Oncopeptides has received a research grant of 3 million SEK from Sweden’s Innovation Agency (Vinnova), to explore the development of new treatment options for glioblastoma, an aggressive and incurable form

The company has announced an increased focus on its strategy around its core AI capabilities allowing fast and de-risked development of its pipeline. Recently, Evaxion announced that the company has

The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for

ObsERV identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients,

The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform

In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry

Affibody and Chiesi Group have announced the execution of a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s technology. Under the terms of

Aqilion has announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. “We

The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. This follows on from the first close of 10 million EUR in June